Plasmalogen Supplementation Prevents Neurodegeneration (C103)

Animals pretreated with plasmalogen supplements are protected against the neurotoxin MPTP. MPTP selectively targets dopamine neurons and creates symptoms and neuropathology similar to Parkinson’s disease.  

To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C103, Supplements (Series C).

Parkinson’s disease is a neurodegenerative disease that affects a specific type of neuron, called a dopamine neuron, in a particular region of the brain, called the substantia nigra. MPTP is a neurotoxin that selectively targets and kills these dopamine neurons and creates Parkinson-like symptoms. This seminar describes the biochemical mechanism of MPTP and how plasmalogen precursor treatment protects dopamine neurons from neurodegeneration.  

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was accidentally discovered as a selective dopamine neuron neurotoxin by a group of amateur drug makers in California in the 1980s. They were trying to make designer heroin that was not on the U.S. Drug Enforcement Agency (DEA) controlled substance list. However, the final drug material that they made was contaminated with MPTP. When they injected themselves with this new “synthetic” heroin, they ended up having a toxic reaction that resulted in them exhibiting symptoms of Parkinson’s disease. After a bit of scientific detective work, MPTP was discovered as the cause of neurodegeneration. From this discovery, a whole bunch of research was done to understand all the nitty-gritty details of how MPTP kills dopamine neurons. MPTP is a prodrug or precursor to MPP+. MPTP enters the brain and then gets metabolized to MPP+, the toxic agent.  

Parkinson’s disease is a movement disorder caused by the degeneration of a specific type of neuron in the brain called a dopamine neuron. Dopamine neurons are called dopamine neurons because they use dopamine as their neurotransmitter. The principle of dopamine neurotransmission is the same as I described earlier for acetylcholine neurons. After the released dopamine interacts with the postsynaptic neuron, it is re-absorbed back into the presynaptic neuron. There is a special dopamine-specific transporter that performs this task. It turns out that this transporter recognizes MPP+ as if it is dopamine. Since only dopamine neurons have the dopamine transporter, MPP+ is selectively absorbed and concentrated into dopamine neurons. MPP+ is toxic to all cells and neurons. It is selectively toxic to dopamine neurons because of the dopamine transporter. Since MPP+ selectively targets only one neuron cell type, it is an invaluable scientific model to study the mechanisms of neurodegeneration applicable to other neurons without having the whole brain affected. Once MPP+ is in the presynaptic dopamine neuron, it has the following negative consequences. 

  1. MPP+ is also recognized by the protein that transports dopamine into the presynaptic vesicles (called the vesicular monoamine transporter or VMAT). These presynaptic vesicles store the dopamine neurotransmitters before their release during a neuron transmission event. MPP+ pushes dopamine out of the vesicles resulting in increased cytosolic dopamine and dopamine leaking out of the cell when at rest. This results in less dopamine being released by the neuron during a neuron transmission pulse. Sequestering the MPP+ in the vesicles reduces dopamine transmission but also reduces the toxicity of MPP+ to the neuron.  
  1. MPP+ induces reactive oxygen species (ROS), commonly referred to as “oxidative stress”. This is what ultimately causes the death of the neuron. 
  1. MPP+ also inhibits the transport of mitochondria from the cell body through the axon to the synapse region. This effect of MPP+ is completely neutralized by restoring glutathione with N-acetylcysteine.  

The terms “oxidative stress” and “reactive oxygen species or ROS” are frequently used when describing a negative or toxic effect on a cell system. ROS are natural and essential products of normal and healthy human biochemistry. They are also vital signaling molecules. Like all things, it is when they are found in excess and in the wrong places that they cause problems. MPP+ toxicity is as good a model as any to explain ROS biochemistry and how it can kill if it is not controlled.  

MPP+ is absorbed into mitochondria where it binds to and inhibits a key protein of the electron transport chain (ETC). This is what triggers a chain of reactions that a normal neuron cannot survive, but a plasmalogen supplemented one can. The human body uses oxygen in many different processes. It uses oxygen to detoxify and remove xenobiotics and to make metabolic intermediates. But oxygen is mostly used to burn hydrocarbons and make energy. The energy released from this reaction is used to drive all the processes of the body. Each of the trillions of cells in your body is on fire, burning hydrocarbons and creating carbon dioxide and water. This is a tightly controlled process. The main purpose of the mitochondria is to convert hydrocarbon energy (an acetyl-CoA metabolite) into biochemical energy (ATP). The mitochondria do this by burning the hydrocarbon into carbon dioxide and water, just like your car engine, and capturing the energy released in ATP. It is supposed to work in two steps. The first step is the citric acid cycle, where the creation of carbon dioxide and the high-energy protonated metabolites NADH and FADH2 occurs. These high-energy metabolites are then handed over to the ETC, which will ultimately use oxygen to convert these protons into water and capture their energy in ATP. The first step of the ETC is to recycle NADH back to NAD+ so that it can go back and convert more acetyl-CoA into carbon dioxide. MPP+ blocks this process and results in both a depletion of NAD+ (which shuts down the citric acid cycle) and an accumulation of NADH (which must go somewhere). If NADH cannot be processed by the ETC, it ends up being processed by NADH oxidase, which is in the outer plasma membrane of the cell, especially at the synapse region of a neuron. Here, it will combine with molecular oxygen and an electron donor to recycle the NAD+ and create a superoxide radical (O2-). This superoxide radical is then neutralized by superoxide dismutase (SOD) into peroxide and then the peroxide is neutralized by catalase or glutathione peroxidase. Like all systems, there are limits. If too much superoxide and peroxide is being formed outside the cell, then these ROS begin to oxidize the lipids in the membrane. A cell is not supposed to have oxidized membrane lipids. This only happens to cells that have serious internal metabolism issues. When this happens, it acts as a signal to your body’s immune system that this cell is about to die. This attracts the microglia to come to the cell and finish the death sentence and clean up the mess. This is the biochemical process of inflammation. 

These features of MPP+ toxicity make this an ideal model to investigate the effects of ADG plasmalogen precursors as a neuroprotectant. The process to create a modest but reproducible degeneration of dopamine neurons is to inject the MPTP toxin in mice four times, every two hours on Day 0, and then wait five days for the degeneration to stabilize. We performed three experiments with the DHA-ADG: 

  1. Treatment with three different dose levels of DHA-ADG for five days before injecting the MPTP toxin. 
  1. Treatment with three different dose levels of DHA-ADG starting one hour after injecting the MPTP toxin and continuing for the next five days.  
  1. Treatment with three different dose levels of DHA-ADG on normal mice for ten days.  

The results were dramatic: 

  1. MPTP treatment resulted in a persistent and residual 15-20% reduction in blood plasmalogen levels five days after treatment with the neurotoxin. The pre-treatment of 10 mg/kg and 50 mg/kg of the plasmalogen precursor completely prevented MPTP depletion of plasmalogens. 
  1. MPTP treatment resulted in the degeneration of approximately 50% of the dopamine neurons and the depletion of both dopamine and serotonin levels. Both the 10 mg/kg and the 50 mg/kg doses resulted in complete protection from neurodegeneration. 
  1. In the post-treatment study, no effect was observed at 10 mg/kg, but a 50% improvement was seen at the 50 mg/kg dose. 

These data contain several important observations.  

  1. They show that plasmalogen reserves are affected by oxidative neurotoxins. 
  1. That neurodegeneration takes a significant amount of time. 
  1. That a pre-existing reserve capacity of plasmalogens can absorb insults and prevent this depletion. 
  1. The mechanism of neurodegeneration by MPTP has been extensively studied. We know that MPTP only becomes toxic to neurons after it crosses the blood-brain barrier and after it is activated by the glia into MPP+ and after it is taken up into the dopamine neuron.  
  1. To protect the dopamine neuron, the DHA-plasmalogen precursor must be acting at or in the dopamine neuron. Therefore, the DHA-plasmalogen precursor enters and is active in the brain.  
  1. We know that the neuronal death caused by MPTP is caused by ROS at the membrane. Therefore, the DHA-plasmalogen precursor must be deactivating it, which is what the vinyl ether bond in plasmalogens is designed to do. 
  1. The pre-treatment with a DHA-plasmalogen precursor to create a DHA-plasmalogen reserve and the maintenance of DHA-plasmalogen supply via continued supplementation performed exactly as predicted.  

Since the mouse studies were purely focused on neuropathology endpoints and did not evaluate neurological function, we also investigated DHA-plasmalogen precursor therapy on monkeys with confirmed Parkinson’s disease caused by past MPTP toxicity. These monkeys respond to L-DOPA therapy in the same way that humans do. After being chronically treated with L-DOPA, these monkeys get side-effects from L-DOPA called L-DOPA induced dyskinesias or LID, which are abnormal limb movements. When we treated these monkeys with 50 mg/kg of the DHA-plasmalogen precursor, there was a noticeable and significant reduction in LID after only two days, and this effect was observed for the entire 12 days of the study. These results indicate that DHA-plasmalogen supplementation has a positive neurological effect in pre-existing neurologically damaged animals. 

Overall, these two MPTP neurodegeneration studies show that DHA-plasmalogen supplementation is neuroprotective against oxidative neurotoxins and neurologically active in neurologically damaged animals. 

Dr. Goodenowe explains the relevant research and literature regarding plasmalogen precursors and the prevention neurodegeneration using Parkinson’s disease as an example in seminar C103 – Plasmalogen Supplementation Prevents Neurodegeneration. 

Share on facebook
Share on twitter
Share on linkedin
privacy
Your privacy is important to us.

To better protect your privacy, we provide this notice explaining our online information practices and the choices you can make about the way your information is collected and used. To make this notice easy to find, we make it available on our homepage and at every point where personally identifiable information may be requested.

Collection of Personal Information

When visiting drdayangoodenowe.com, the IP address used to access the site will be logged along with the dates and times of access. This information is purely used to analyze trends, administer the site, track users’ movement and gather broad demographic information for internal use. Most important, any recorded IP addresses are not linked to personally identifiable information.

Links to Third-Party Websites
We have included links on this site for your use and reference. We are not responsible for the privacy policies on these websites. You should be aware that the privacy policies of these sites may differ from our own.
Our Use of Google Analytics
The Dr. Dayan Goodenowe website uses the Google Analytics tool to measure traffic on the site and traffic to the site via our online advertising. This includes using certain Advertising Features, which enable Google Analytics to collect data about users via Google advertising cookies and identifiers, in addition to anonymous data collected through the standard Google Analytics implementation. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
  • Remarketing with Google Analytics. This allows us to display our ads to you as you search online for similar businesses.
  • Google Display Network Impression Reporting, which shows which of our ads users click on.
  • Google Analytics Demographics and Interest Reporting, which provides information about the age and gender of site users, along with the interests they express in their online travel and purchasing activities.
  • Integrated services that require Google Analytics to collect data via advertising cookies and identifiers.
We do not merge personally identifiable information with non-personally identifiable information collected through any Google advertising product or feature unless we have obtained robust notice of, and the user’s prior affirmative (i.e., opt-in) consent to, that merger. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
Opt Out

There are several ways to opt out of interest-based advertising and/or all tracking related to Google Analytics and its advertising features.
You can opt out of interest-based ads by Google through Ads Settings. When you opt out, you’ll still see ads but they may not be related to factors such as your interests, previous visits to other websites, or demographic details. Obtain instructions here.

The Network Advertising Initiative offers a free tool that allows users to opt out from receiving interest-based ads from some or all NAI participating member companies that use cookies on your computer browser to collect data for interest-based advertising. Find information about it here.

Website visitors can totally block Google Analytics with the Google Analytics opt-out browser add-on (click to download). This add-on instructs the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) running on websites to prohibit their information from being used by Google Analytics. Using the Google Analytics opt-out plug-in will not prevent site owners from using other tools to measure site analytics. Learn more about about the opt-out and how to properly install the browser add-on here.

Changes to this Privacy

Statement The contents of this statement may be altered at any time, at our discretion.

If you have any questions regarding the privacy policy of drdayangoodenowe.com then you may contact us at info@drdayangoodenowe.com

terms of use
Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern drdayangoodenowe.com’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.

The term ‘drdayangoodenowe.com’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is:

40880 County Center Drive
Suite R
Temecula, CA 92591, USA

The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of Canada and USA.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don’t tell us who you are. If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies.

This site is not a part of the Facebook website or Facebook Inc. Additionally, this site is not endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.